MAPT and Alzheimer disease: The clinical measures (mini‐mental‐state examination (MMSE) score, polygenic hazard score (PHS), fludeoxyglucose (FDG), Alzheimer's disease assessment scale–cognitive subscale (ADAS‐cog11 score and ADAS‐cog13 score), cerebrospinal fluid (CSF) amyloid‐beta (Aβ) level, CSF Tau level, CSF P‐tau level, cognitive domain composite scores, and auditory‐verbal learning test (AVLT) score) were significantly different among the NC, MCI, and AD groups (p < 0.001 with Analysis of Variance (ANOVA), Bonferroni corrected) (Table 1).